Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 2/20 | 0.53 |
| ▸ | CASP7 | P55210 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11068379 | 0.83 | MAOA (0.52) | ALDH1A1KDM4EGLASMN1; SMN2TDP1 | |
| SCHEMBL27832433 | 0.83 | PDE10A (0.47) | ALDH1A1KDM4EGLAGAAKMT2A | |
| SCHEMBL672454 | 0.81 | CYP1A2 (0.61) | ALDH1A1KDM4EHSD17B10GLAHPGD | |
| SCHEMBL27935140 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10GLAHPGD | |
| SCHEMBL13701018 | 0.76 | ALDH1A1 (0.53) | ALDH1A1KDM4EHSD17B10GLAHPGD | |
| SCHEMBL17066273 | 0.76 | CYP1A2 (0.64) | ALDH1A1KDM4EHSD17B10GLAHPGD | |
| SCHEMBL28055296 | 0.76 | CYP1A2 (0.55) | ALDH1A1KDM4EHSD17B10GLAHPGD | |
| SCHEMBL3458914 | 0.75 | ALDH1A1 (0.65) | ALDH1A1KDM4EHSD17B10GLAHPGD | |
| SCHEMBL5748273 | 0.75 | KDM4E (0.62) | ALDH1A1KDM4EHSD17B10GLAHPGD | |
| Hydrochloric Acid SCHEMBL3242596 | 0.74 | RAB9A (0.67) | ALDH1A1KDM4EHSD17B10GLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549312-A1 | SEQUENTIAL THERAPY COMPRISING A 20(S)-CAMPTOTHECIN AND AN ANTHRACYCLINE | SuperGen, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040097437-A1 | Sequential therapy comprising a 20(S)-camptothecin and an anthracycline | SUPERGEN, INC., A DELAWARE CORPORATION | 2004-05-20 | — | — | US | disclosed |
| WO-2003103672-A1 | SEQUENTIAL THERAPY COMPRISING A 20(S)-CAMPTOTHECIN AND AN ANTHRACYCLINE | SUPERGEN, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-6627614-B1 | Treating a patient having a disease associated with undesirable or uncontrolled cell proliferation. The method comprises: administering to the patient an anthracycline for a period of time during which a 20(S)-camptothecin is not | SUPER GEN, INC. | 2003-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097437-A1 | Sequential therapy comprising a 20(S)-camptothecin and an anthracycline | TOP2A, TOP1, TOP2B | ALDH1A1 1398/4885KDM4E 3819/4885HSD17B10 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.